PTC Therapeutics price target raised to $113 from $76 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on PTC Therapeutics (PTCT) to $113 from $76 and keeps an Overweight rating on the shares. PTC has several regulatory decisions this year, and Cantor remains most bullish on sepiapterin, an oral precursor to enzymatic cofactor, for phenylketonuri, the analyst tells investors in a research note. The firm says it is “incredibly bullish” around the profile of this drug, which it says offers clear benefits over standard of care KUVAN.